Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Abrau-Durso will produce cosmetics for hotels

5/18/23 ABRD

PJSFC Sistema delisted from LSE and started conversion of receipts

5/18/23 AFKS

Take-Two Interactive Software reported for fiscal year 2023

5/18/23 TTWO

The Cisco Systems announced a quarterly dividend

5/18/23 CSCO

Cisco reported for 9 months of fiscal year 2023

5/18/23 CSCO

Bank Saint-Petersburg reported for 3 months of 2023 by RAS

5/18/23 BSPB

Year-round navigation in the eastern direction of the Northern Sea Route will start in 2024

5/17/23 NVTK

VTB became the first Russian bank to open a representative office in Iran

5/17/23 VTBR

Rosbank reported for 3 months of 2023 by IFRS

5/17/23 ROSB

Alrosa's Supervisory Board approved Pavel Marynichev for the position of General Director

5/17/23 ALRS